Table 5.
Trials of multiple sclerosis (MS) therapies that are active but no longer recruiting, or that have been withdrawn, suspended or terminated. Trials are only listed if disability endpoints were specified
| Trial name | Intervention(s) | Patient group | Comment |
|---|---|---|---|
| Active trials—oral therapies | |||
| CHOLINE NCT01198132 |
Cholecalciferol as add-on to subcutaneous IFN beta-1a | RRMS | |
| CONTAIN NCT01514370 |
Curcumin as add-on to subcutaneous IFN beta-1a | Early active RMS | |
| NCT00835770 | Dimethyl fumarate | RRMS | Combined extension to CONFIRM and DEFINE |
| INFORMS NCT00731692 |
Fingolimod | PPMS | |
| NCT01047319 | Laquinimod | RMS | BRAVO extension |
| NCT01188811 | Lipoic acid | SPMS | |
| MS-SPI NCT02220933 |
MD1003 | Spinal PMS | |
| SUPREMES NCT00799890 |
Sunphenon | PPMS SPMS |
|
| NCT00803049 | Teriflunomide | RRMS | TEMSO extension |
| NCT00228163 | Teriflunomide | RMS | Phase II 10-year follow-up |
| SOLAR NCT01285401 |
VigantOL® oil as add-on to subcutaneous IFN beta-1a | RRMS | |
| Active trials—intravenous therapies | |||
| ACCLAIM NCT01116427 |
Abatacept | RRMS | |
| NCT01433250 | AIN457 (secukinumab) | RRMS | Phase II |
| NCT00930553 | Alemtuzumab | RRMS | Extension to CAMMS223, CARE-MS I and CARE-MS II |
| SYNERGY NCT01864148 |
BIIB033 (anti-LINGO-1) with intramuscular IFN beta-1a | RMS | |
| ASCEND NCT01416181 |
Natalizumab | SPMS | |
| NCT01416155 | Natalizumab | RRMS | Phase II Japanese study extension |
|
NCT01412333 NCT01247324 |
Ocrelizumab ± subcutaneous IFN beta-1a | RRMS | |
| NCT01194570 | Ocrelizumab + methylprednisolone | PPMS | |
| GATEWAY II NCT01569451 |
Rituximab then subcutaneous GA | CIS RMS |
|
| Active trials—injectable therapies | |||
| DECIDE NCT01064401 |
Subcutaneous daclizumab + IFN beta-1a | RRMS | Pivotal phase III trial |
| SELECTED NCT01051349 |
Subcutaneous daclizumab | RRMS | SELECT extension |
| ATTAIN NCT01332019 |
Subcutaneous pegylated IFN beta-1a | RRMS | Phase III ADVANCE extension |
| Withdrawn trials—oral therapies | |||
| NCT00296205 | High-dose cyclophosphamide | SPMS PPMS PRMS |
Principal investigator changed institution |
| NCT00104143 | A4i antagonist | RMS | Withdrawn before enrollment |
| NCT00429442 | Simvastatin as add-on to GA | RMS | Withdrawn before enrollment |
| Suspended trials—intravenous therapies | |||
| NCT00939549 | High-dose cyclophosphamide then subcutaneous GA | RRMS | Suspended for revisions to protocol |
| NCT01039103 | Nanocort in acute exacerbation | RRMS | No reason given |
| Terminated trials—oral therapies | |||
| TERACLES NCT01252355 |
Teriflunomide | RRMS | Sponsor decision, not linked to safety |
| TOFINGO NCT01499667 |
Fingolimod | RRMS | Determination of natalizumab washout period no longer relevant |
| RECYCLINE NCT01134627 |
Minocycline | RRMS | No reason recorded |
| NCT00418145 | Oral (vs intravenous) steroids | RMS | Low enrollment |
| NCT01516554 | Oral testosterone for fatigue | RRMS | No reason recorded |
| NCT01037907 | BGC20-0134 | RRMS | Lack of efficacy |
| FLORIMS NCT00623415 |
Flupirtine | RRMS | |
| Memantine-MS NCT00638833 |
Memantine | All MS types | Unexpected, reversible, mild-to-moderate neurological impairment |
| Terminated trials—intravenous therapies | |||
| NCT00146159 | Mitoxantrone | SPMS | No reason recorded |
| NCT00219908 | Mitoxantrone | Early active RRMS | No reason recorded |
| MAESTRO-02 NCT00870155 |
MBP8298 | SPMS | Negative efficacy in MAESTRO-01 |
| MAESTRO-03 NCT00468611 |
MBP8298 | SPMS | Negative efficacy in MAESTRO-01 |
| STRATA NCT00297232 |
Natalizumab | RMS | No reason recorded |
| Terminated trials—injectable therapies | |||
| RECLAIM NCT00947895 |
ACTH | RRMS | Study halted after 1 year for data analysis |
| ATAMS extension NCT00853762 |
Atacicept | Increased MS disease activity in ATAMS | |
| NCT00313976 | Subcutaneous IFN beta-1b (double dose) | SPMS | No reason recorded |
| SURPASS NCT01058005 |
Subcutaneous IFN beta-1a + subcutaneous GA + natalizumab | RRMS | Terminated by sponsor because of low enrollment |
| NCT00784836 | Subcutaneous IFN beta-1a (Avonex®) | RRMS | Terminated by sponsor for reasons unrelated to safety |
ACTH adrenocorticotrophic hormone, CIS clinically isolated syndrome, GA glatiramer acetate, IFN interferon, MS multiple sclerosis, PPMS primary progressive MS, PRMS progressive relapsing MS, RMS relapsing MS, RRMS relapsing–remitting MS, SPMS secondary progressive MS